EP0810853B1
(de)
*
|
1995-02-24 |
2004-08-25 |
Elan Pharma International Limited |
Nanopartikel-dispersionen enthaltende aerosole
|
US6465016B2
(en)
*
|
1996-08-22 |
2002-10-15 |
Research Triangle Pharmaceuticals |
Cyclosporiine particles
|
US7255877B2
(en)
*
|
1996-08-22 |
2007-08-14 |
Jagotec Ag |
Fenofibrate microparticles
|
US6045829A
(en)
*
|
1997-02-13 |
2000-04-04 |
Elan Pharma International Limited |
Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
|
US20050004049A1
(en)
*
|
1997-03-11 |
2005-01-06 |
Elan Pharma International Limited |
Novel griseofulvin compositions
|
UA72189C2
(uk)
|
1997-11-17 |
2005-02-15 |
Янссен Фармацевтика Н.В. |
Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
|
EP1079808B1
(de)
|
1998-05-29 |
2004-02-11 |
Skyepharma Canada Inc. |
Gegen hitzeeinwirkung geschützte mikropartikel und verfahren zur terminalen dampfsterilisation derselben
|
US20080213378A1
(en)
*
|
1998-10-01 |
2008-09-04 |
Elan Pharma International, Ltd. |
Nanoparticulate statin formulations and novel statin combinations
|
EP1117384A1
(de)
*
|
1998-10-01 |
2001-07-25 |
Elan Pharma International Limited |
Nanopartikelformulierungen mit kontrollierter wirkstofffreisetzung
|
US20040013613A1
(en)
*
|
2001-05-18 |
2004-01-22 |
Jain Rajeev A |
Rapidly disintegrating solid oral dosage form
|
US8293277B2
(en)
*
|
1998-10-01 |
2012-10-23 |
Alkermes Pharma Ireland Limited |
Controlled-release nanoparticulate compositions
|
US8236352B2
(en)
*
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
JP4613275B2
(ja)
*
|
1998-11-02 |
2011-01-12 |
エラン ファーマ インターナショナル,リミティド |
多粒子改質放出組成物
|
US20090297602A1
(en)
*
|
1998-11-02 |
2009-12-03 |
Devane John G |
Modified Release Loxoprofen Compositions
|
US6969529B2
(en)
|
2000-09-21 |
2005-11-29 |
Elan Pharma International Ltd. |
Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
|
US7521068B2
(en)
*
|
1998-11-12 |
2009-04-21 |
Elan Pharma International Ltd. |
Dry powder aerosols of nanoparticulate drugs
|
US6375986B1
(en)
|
2000-09-21 |
2002-04-23 |
Elan Pharma International Ltd. |
Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
|
US20040141925A1
(en)
*
|
1998-11-12 |
2004-07-22 |
Elan Pharma International Ltd. |
Novel triamcinolone compositions
|
CZ20011739A3
(cs)
|
1998-11-20 |
2001-10-17 |
Rtp Pharma Inc. |
Dispergovatelné fosfolipidem stabilizované mikročástice
|
DE19856432A1
(de)
*
|
1998-12-08 |
2000-06-15 |
Basf Ag |
Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
|
US20090104273A1
(en)
*
|
1999-06-22 |
2009-04-23 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
US20040115134A1
(en)
*
|
1999-06-22 |
2004-06-17 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
ES2241663T3
(es)
*
|
1999-09-21 |
2005-11-01 |
Skyepharma Canada Inc. |
Composiciones particuladas modificadas superficialmente de substancias biologicamente activas.
|
WO2001034119A2
(en)
|
1999-11-12 |
2001-05-17 |
Abbott Laboratories |
Inhibitors of crystallization in a solid dispersion
|
SI1611892T1
(sl)
*
|
2000-01-18 |
2010-01-29 |
Bayer Schering Pharma Ag |
Farmacevtski sestavki, ki obsegajo drospirenon
|
DE60124080T2
(de)
|
2000-03-23 |
2007-03-01 |
Elan Pharmaceuticals, Inc., San Francisco |
Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
|
US6992081B2
(en)
|
2000-03-23 |
2006-01-31 |
Elan Pharmaceuticals, Inc. |
Compounds to treat Alzheimer's disease
|
US6316029B1
(en)
*
|
2000-05-18 |
2001-11-13 |
Flak Pharma International, Ltd. |
Rapidly disintegrating solid oral dosage form
|
DE10026698A1
(de)
*
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
IN192188B
(de)
*
|
2000-06-16 |
2004-03-13 |
Ranbaxy Lab Ltd |
|
US20030096864A1
(en)
*
|
2000-06-30 |
2003-05-22 |
Fang Lawrence Y. |
Compounds to treat alzheimer's disease
|
US6846813B2
(en)
*
|
2000-06-30 |
2005-01-25 |
Pharmacia & Upjohn Company |
Compounds to treat alzheimer's disease
|
JP2004502664A
(ja)
*
|
2000-06-30 |
2004-01-29 |
イーラン ファーマスーティカルズ、インコーポレイテッド |
アルツハイマー病処置用化合物
|
PE20020276A1
(es)
|
2000-06-30 |
2002-04-06 |
Elan Pharm Inc |
COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
|
EP1666452A2
(de)
|
2000-06-30 |
2006-06-07 |
Elan Pharmaceuticals, Inc. |
Verbindungen zur Behandlung der Alzheimerischen Krankheit
|
US7198795B2
(en)
*
|
2000-09-21 |
2007-04-03 |
Elan Pharma International Ltd. |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
|
US7998507B2
(en)
*
|
2000-09-21 |
2011-08-16 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
|
US20030224058A1
(en)
*
|
2002-05-24 |
2003-12-04 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
US7276249B2
(en)
*
|
2002-05-24 |
2007-10-02 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
US20080241070A1
(en)
*
|
2000-09-21 |
2008-10-02 |
Elan Pharma International Ltd. |
Fenofibrate dosage forms
|
WO2002094215A2
(en)
*
|
2000-11-20 |
2002-11-28 |
Elan Pharma International Ltd. |
Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vimyl acetate as surface stabilizers
|
US6951656B2
(en)
*
|
2000-12-22 |
2005-10-04 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
US6884436B2
(en)
*
|
2000-12-22 |
2005-04-26 |
Baxter International Inc. |
Method for preparing submicron particle suspensions
|
US9700866B2
(en)
*
|
2000-12-22 |
2017-07-11 |
Baxter International Inc. |
Surfactant systems for delivery of organic compounds
|
US8067032B2
(en)
|
2000-12-22 |
2011-11-29 |
Baxter International Inc. |
Method for preparing submicron particles of antineoplastic agents
|
US20030096013A1
(en)
*
|
2000-12-22 |
2003-05-22 |
Jane Werling |
Preparation of submicron sized particles with polymorph control
|
US6869617B2
(en)
|
2000-12-22 |
2005-03-22 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
US7193084B2
(en)
*
|
2000-12-22 |
2007-03-20 |
Baxter International Inc. |
Polymorphic form of itraconazole
|
US20040256749A1
(en)
*
|
2000-12-22 |
2004-12-23 |
Mahesh Chaubal |
Process for production of essentially solvent-free small particles
|
US20050048126A1
(en)
*
|
2000-12-22 |
2005-03-03 |
Barrett Rabinow |
Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
|
US6977085B2
(en)
*
|
2000-12-22 |
2005-12-20 |
Baxter International Inc. |
Method for preparing submicron suspensions with polymorph control
|
AU2002234219A1
(en)
*
|
2001-03-09 |
2002-09-24 |
Dow Global Technologies Inc. |
Granular composition comprising an active compound and a cellulose ether and the use thereof
|
CZ20033211A3
(cs)
*
|
2001-05-03 |
2004-09-15 |
F. Hoffmann-La Roche Ag |
Farmaceutická léková forma amorfního nelfinavir mesylátu
|
US6976647B2
(en)
*
|
2001-06-05 |
2005-12-20 |
Elan Pharma International, Limited |
System and method for milling materials
|
MXPA03011521A
(es)
|
2001-06-13 |
2004-03-18 |
Elan Pharm Inc |
Aminadioles para tratamiento de enfermedad de alzheimer.
|
JP2004534811A
(ja)
*
|
2001-06-22 |
2004-11-18 |
ファイザー・プロダクツ・インク |
ポリマーと薬剤の集合体を含む医薬組成物
|
ATE291899T1
(de)
*
|
2001-06-22 |
2005-04-15 |
Marie Lindner |
Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics
|
US6982264B2
(en)
*
|
2001-06-27 |
2006-01-03 |
Elan Pharmaceuticals, Inc. |
Substituted alcohols useful in treatment of Alzheimer's disease
|
US20070213407A1
(en)
*
|
2001-06-29 |
2007-09-13 |
Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc |
Compounds to treat Alzheimer's disease
|
CA2453451A1
(en)
*
|
2001-07-10 |
2003-01-23 |
Elan Pharmaceuticals, Inc. |
Aminediols for the treatment of alzheimer's disease
|
US7067542B2
(en)
*
|
2001-07-10 |
2006-06-27 |
Pharmacia & Upjohn Company |
Diaminediols for the treatment of Alzheimer's disease
|
US7297553B2
(en)
*
|
2002-05-28 |
2007-11-20 |
Nanosphere, Inc. |
Method for attachment of silylated molecules to glass surfaces
|
MY169670A
(en)
*
|
2003-09-03 |
2019-05-08 |
Tibotec Pharm Ltd |
Combinations of a pyrimidine containing nnrti with rt inhibitors
|
US20030054042A1
(en)
*
|
2001-09-14 |
2003-03-20 |
Elaine Liversidge |
Stabilization of chemical compounds using nanoparticulate formulations
|
DK1429731T3
(da)
*
|
2001-09-19 |
2007-05-14 |
Elan Pharma Int Ltd |
Nanopartikelformuleringer indeholdende insulin
|
BR0212833A
(pt)
*
|
2001-09-26 |
2004-10-13 |
Baxter Int |
Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
|
US20060003012A9
(en)
*
|
2001-09-26 |
2006-01-05 |
Sean Brynjelsen |
Preparation of submicron solid particle suspensions by sonication of multiphase systems
|
BR0213139A
(pt)
|
2001-10-04 |
2004-08-10 |
Elan Pharm Inc |
Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica
|
JP2005508939A
(ja)
*
|
2001-10-12 |
2005-04-07 |
エラン ファーマ インターナショナル,リミティド |
即時放出および徐放特性を組み合わせて有する組成物
|
US20040015519A1
(en)
*
|
2001-10-15 |
2004-01-22 |
Yukitoshi Maeda |
Content delivery server and content delivery system having the same
|
US7112340B2
(en)
*
|
2001-10-19 |
2006-09-26 |
Baxter International Inc. |
Compositions of and method for preparing stable particles in a frozen aqueous matrix
|
NZ533107A
(en)
*
|
2001-11-08 |
2007-04-27 |
Upjohn Co |
N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
|
WO2003043618A2
(en)
*
|
2001-11-19 |
2003-05-30 |
Elan Pharmaceuticals, Inc. |
Amino diols useful in the treatment of alzheimer's disease
|
UA76810C2
(uk)
*
|
2001-12-10 |
2006-09-15 |
Мерк Енд Ко., Інк. |
Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок
|
US20030129242A1
(en)
*
|
2002-01-04 |
2003-07-10 |
Bosch H. William |
Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
|
US20040101566A1
(en)
*
|
2002-02-04 |
2004-05-27 |
Elan Pharma International Limited |
Novel benzoyl peroxide compositions
|
ATE464880T1
(de)
*
|
2002-02-04 |
2010-05-15 |
Elan Pharma Int Ltd |
Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
|
CA2479735C
(en)
*
|
2002-03-20 |
2011-05-17 |
Elan Pharma International Ltd. |
Fast dissolving dosage forms having reduced friability
|
CA2479665C
(en)
*
|
2002-03-20 |
2011-08-30 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of angiogenesis inhibitors
|
US20080220075A1
(en)
*
|
2002-03-20 |
2008-09-11 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of angiogenesis inhibitors
|
US20100226989A1
(en)
*
|
2002-04-12 |
2010-09-09 |
Elan Pharma International, Limited |
Nanoparticulate megestrol formulations
|
US20040105889A1
(en)
*
|
2002-12-03 |
2004-06-03 |
Elan Pharma International Limited |
Low viscosity liquid dosage forms
|
US9101540B2
(en)
|
2002-04-12 |
2015-08-11 |
Alkermes Pharma Ireland Limited |
Nanoparticulate megestrol formulations
|
US7101576B2
(en)
*
|
2002-04-12 |
2006-09-05 |
Elan Pharma International Limited |
Nanoparticulate megestrol formulations
|
EP2263650A3
(de)
|
2002-04-12 |
2013-12-25 |
Alkermes Pharma Ireland Limited |
Nanopartikuläre Megestrol- Formulierungen
|
WO2004058686A1
(en)
*
|
2002-04-30 |
2004-07-15 |
Elan Pharmaceuticals, Inc. |
Hydroxypropyl amides for the treatment of alzheimer’s disease
|
ATE419835T1
(de)
*
|
2002-05-06 |
2009-01-15 |
Elan Pharma Int Ltd |
Nystatin-nanopartikelzusammensetzungen
|
US20070264348A1
(en)
*
|
2002-05-24 |
2007-11-15 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
CA2488499C
(en)
*
|
2002-06-10 |
2013-03-19 |
Elan Pharma International Ltd. |
Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"),combinations thereof as well as manufacturing of these pharmaceutical compositions
|
WO2003103632A1
(en)
*
|
2002-06-10 |
2003-12-18 |
Elan Pharma International, Ltd. |
Nanoparticulate polycosanol formulations and novel polycosanol combinations
|
US20040258757A1
(en)
*
|
2002-07-16 |
2004-12-23 |
Elan Pharma International, Ltd. |
Liquid dosage compositions of stable nanoparticulate active agents
|
ES2333318T3
(es)
|
2002-08-12 |
2010-02-19 |
Bend Research, Inc. |
Composiciones farmaceuticas de medicamentos con estructura semiordenada y de polimero.
|
US7713551B2
(en)
*
|
2002-09-11 |
2010-05-11 |
Elan Pharma International Ltd. |
Gel stabilized nanoparticulate active agent compositions
|
EP1556091A1
(de)
*
|
2002-10-04 |
2005-07-27 |
Elan Pharma International Limited |
Gamma-bestrahlung von festen aktivmaterialien in nanopartikularer form
|
WO2004043440A1
(en)
*
|
2002-11-12 |
2004-05-27 |
Elan Pharma International Ltd. |
Fast-disintegrating solid dosage forms being not friable and comprising pullulan
|
CA2506839A1
(en)
*
|
2002-11-20 |
2004-06-03 |
Arriva-Prometic Inc. |
Composition and method for treating inflammatory diseases using protease inhibitors
|
AU2003293155A1
(en)
*
|
2002-11-27 |
2004-06-23 |
Elan Pharmaceutical, Inc. |
Substituted ureas and carbamates
|
WO2004058216A2
(en)
*
|
2002-12-17 |
2004-07-15 |
Elan Pharma International Ltd. |
Milling microgram quantities of nanoparticulate candidate compounds
|
EP1587499A1
(de)
*
|
2003-01-31 |
2005-10-26 |
Elan Pharma International Limited |
Nanopartikuläre topiramat formulierung
|
US20040208833A1
(en)
*
|
2003-02-04 |
2004-10-21 |
Elan Pharma International Ltd. |
Novel fluticasone formulations
|
CA2516642C
(en)
*
|
2003-02-21 |
2010-11-23 |
Jarrow Formulas, Inc. |
Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors
|
US20100297252A1
(en)
|
2003-03-03 |
2010-11-25 |
Elan Pharma International Ltd. |
Nanoparticulate meloxicam formulations
|
US8512727B2
(en)
|
2003-03-03 |
2013-08-20 |
Alkermes Pharma Ireland Limited |
Nanoparticulate meloxicam formulations
|
EP1615892A2
(de)
*
|
2003-04-21 |
2006-01-18 |
Elan Pharmaceuticals, Inc. |
Benzamid-2-hydroxy-3-diaminoalkane
|
CA2522805A1
(en)
*
|
2003-04-21 |
2004-11-04 |
Elan Pharmaceuticals, Inc. |
Phenacyl 2-hydroxy-3-diaminoalkanes
|
CA2523035C
(en)
*
|
2003-05-22 |
2011-04-26 |
Elan Pharma International Ltd. |
Sterilization of dispersions of nanoparticulate active agents with gamma radiation
|
BRPI0414970A2
(pt)
*
|
2003-06-24 |
2012-12-11 |
Baxter Int |
método para transporte de drogas ao cérebro
|
US8986736B2
(en)
*
|
2003-06-24 |
2015-03-24 |
Baxter International Inc. |
Method for delivering particulate drugs to tissues
|
EA015349B1
(ru)
*
|
2003-07-11 |
2011-06-30 |
Ф. Хоффманн-Ля Рош Аг |
Твёрдая разовая пероральная фармацевтическая дозированная форма саквинавирмезилата и способ её изготовления
|
CA2534924A1
(en)
*
|
2003-08-08 |
2005-02-24 |
Elan Pharma International Ltd. |
Novel metaxalone compositions
|
GB0319797D0
(en)
*
|
2003-08-26 |
2003-09-24 |
Leuven K U Res & Dev |
Particle size reduction of poorly soluble drugs
|
US8377952B2
(en)
*
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
US7879360B2
(en)
*
|
2003-11-05 |
2011-02-01 |
Elan Pharma International, Ltd. |
Nanoparticulate compositions having a peptide as a surface stabilizer
|
AU2004296764B2
(en)
*
|
2003-12-02 |
2011-04-28 |
The Ohio State University Research Foundation |
Zn2+ -chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors
|
US20060014790A1
(en)
*
|
2004-01-21 |
2006-01-19 |
Varghese John |
Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors
|
CN1913871A
(zh)
*
|
2004-01-29 |
2007-02-14 |
巴克斯特国际公司 |
用于提高中枢神经系统投递的抗-逆转录病毒药剂的纳米悬浮液
|
WO2005087215A1
(en)
*
|
2004-03-09 |
2005-09-22 |
Elan Pharmaceuticals, Inc. |
Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
|
JP2007528402A
(ja)
*
|
2004-03-09 |
2007-10-11 |
エラン ファーマシューティカルズ,インコーポレイテッド |
置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
|
CA2556826A1
(en)
*
|
2004-03-09 |
2005-09-22 |
Elan Pharmaceuticals, Inc. |
Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
|
WO2005087751A2
(en)
*
|
2004-03-09 |
2005-09-22 |
Elan Pharmaceuticals, Inc. |
Substituted hydroxyethylamine aspartyl protease inhibitors
|
WO2005117997A1
(en)
*
|
2004-06-01 |
2005-12-15 |
The Ohio State University |
Ligands having metal binding ability and targeting properties
|
BRPI0510271A
(pt)
*
|
2004-06-15 |
2007-10-30 |
Baxter Int |
aplicações ex-vivo agentes terapêuticos microparticulados
|
WO2006002088A2
(en)
*
|
2004-06-21 |
2006-01-05 |
The Ohio State University Research Foundation |
Amino-quinazoline derivatives as antitumor agents
|
JP2008505929A
(ja)
*
|
2004-07-09 |
2008-02-28 |
エラン ファーマシューティカルズ,インコーポレイテッド |
オキシム誘導体ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
|
US7385085B2
(en)
*
|
2004-07-09 |
2008-06-10 |
Elan Pharmaceuticals, Inc. |
Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
|
CA2577392A1
(en)
*
|
2004-08-27 |
2006-03-09 |
Elan Pharmaceuticals, Inc. |
Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
|
CA2577852A1
(en)
|
2004-08-31 |
2006-03-09 |
Pfizer Products Inc. |
Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
|
EP2623095A1
(de)
*
|
2004-11-16 |
2013-08-07 |
Elan Pharma International Limited |
Injizierbare Olanzapin-Formulierungen in Nanoteilchenform
|
UA89513C2
(uk)
*
|
2004-12-03 |
2010-02-10 |
Элан Фарма Интернешнл Лтд. |
Стабільна композиція з наночастинок ралоксифену гідрохлориду
|
US20080145430A1
(en)
*
|
2004-12-08 |
2008-06-19 |
Santipharp Panmai |
Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor
|
CA2590675A1
(en)
*
|
2004-12-15 |
2006-06-22 |
Elan Pharma International Ltd. |
Nanoparticulate tacrolimus formulations
|
WO2006069098A1
(en)
*
|
2004-12-22 |
2006-06-29 |
Elan Pharma International Ltd. |
Nanoparticulate bicalutamide formulations
|
WO2006074218A2
(en)
*
|
2005-01-06 |
2006-07-13 |
Elan Pharma International Ltd. |
Nanoparticulate candesartan formulations
|
US20060198896A1
(en)
|
2005-02-15 |
2006-09-07 |
Elan Pharma International Limited |
Aerosol and injectable formulations of nanoparticulate benzodiazepine
|
EP1855651A4
(de)
*
|
2005-03-03 |
2011-06-15 |
Elan Pharma Int Ltd |
Nanopartikelzusammensetzungen heterocyclischer amidderivate
|
US20060204588A1
(en)
*
|
2005-03-10 |
2006-09-14 |
Elan Pharma International Limited |
Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
|
JP2008533174A
(ja)
*
|
2005-03-16 |
2008-08-21 |
エラン ファーマ インターナショナル リミテッド |
ナノ粒子ロイコトリエン受容体拮抗薬/副腎皮質ステロイド製剤
|
NZ561666A
(en)
*
|
2005-03-17 |
2010-05-28 |
Elan Pharma Int Ltd |
Nanoparticulate biphosphonate compositions
|
BRPI0609700A2
(pt)
*
|
2005-03-23 |
2010-04-20 |
Elan Pharma Int Ltd |
formulações de corticosteróide nanoparticulado e antihistamina
|
US7825087B2
(en)
|
2005-04-12 |
2010-11-02 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising cyclosporine
|
US20060246141A1
(en)
*
|
2005-04-12 |
2006-11-02 |
Elan Pharma International, Limited |
Nanoparticulate lipase inhibitor formulations
|
MX2007012778A
(es)
*
|
2005-04-12 |
2008-01-11 |
Elan Pharma Int Ltd |
Formulaciones de derivados de quinazolina nanoparticuladas.
|
WO2006109177A1
(en)
*
|
2005-04-13 |
2006-10-19 |
Pfizer Products Inc. |
Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
|
JP2008540546A
(ja)
*
|
2005-05-10 |
2008-11-20 |
エラン ファーマ インターナショナル リミテッド |
ナノ粒子クロピドグレル製剤
|
WO2006132752A1
(en)
*
|
2005-05-10 |
2006-12-14 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising vitamin k2
|
US20100028439A1
(en)
*
|
2005-05-23 |
2010-02-04 |
Elan Pharma International Limited |
Nanoparticulate stabilized anti-hypertensive compositions
|
WO2007053197A2
(en)
*
|
2005-06-03 |
2007-05-10 |
Elan Pharma International, Limited |
Nanoparticulate acetaminophen formulations
|
US20070042049A1
(en)
*
|
2005-06-03 |
2007-02-22 |
Elan Pharma International, Limited |
Nanoparticulate benidipine compositions
|
US20060275372A1
(en)
*
|
2005-06-03 |
2006-12-07 |
Elan Pharma International Limited |
Nanoparticulate imatinib mesylate formulations
|
DE112006001606T5
(de)
|
2005-06-08 |
2009-07-09 |
Elan Pharma International Ltd., Athlone |
Nanopartikuläre und eine kontrollierte Freisetzung aufweisende Zusammensetzung, die Cefditoren umfassen
|
ATE446742T1
(de)
*
|
2005-06-09 |
2009-11-15 |
Elan Pharma Int Ltd |
Nanopartikuläre ebastinformulierungen
|
KR20080016952A
(ko)
*
|
2005-06-13 |
2008-02-22 |
엘란 파마 인터내셔널 리미티드 |
나노입자형 클로피도그렐과 아스피린의 배합 제제
|
AU2006259594A1
(en)
*
|
2005-06-14 |
2006-12-28 |
Baxter Healthcare S.A. |
Pharmaceutical formulations for minimizing drug-drug interactions
|
US20060280787A1
(en)
*
|
2005-06-14 |
2006-12-14 |
Baxter International Inc. |
Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
|
CA2612384A1
(en)
*
|
2005-06-15 |
2006-12-28 |
Elan Pharma International, Limited |
Nanoparticulate azelnidipine formulations
|
EP1904041A2
(de)
*
|
2005-07-07 |
2008-04-02 |
Elan Pharma International Limited |
Nanopartikuläre clarithromycinformulierung
|
AU2006269961B2
(en)
*
|
2005-07-15 |
2012-07-19 |
Map Pharmaceuticals, Inc. |
Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
|
WO2007033239A2
(en)
*
|
2005-09-13 |
2007-03-22 |
Elan Pharma International, Limited |
Nanoparticulate tadalafil formulations
|
EP2279727A3
(de)
|
2005-09-15 |
2011-10-05 |
Elan Pharma International Limited |
Nanoteilchenförmige Aripiprazolformulierungen
|
EP1937638A1
(de)
*
|
2005-10-12 |
2008-07-02 |
Elan Pharmaceuticals Inc. |
Verfahren zur behandlung von amyloidose unter verwendung von aspartylproteaseinhibitor- arylcyclopropylderivaten
|
WO2007047305A1
(en)
*
|
2005-10-12 |
2007-04-26 |
Elan Pharmaceuticals, Inc. |
Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
|
EP1954245A2
(de)
*
|
2005-11-15 |
2008-08-13 |
Baxter International Inc. |
Zusammensetzungen aus lipoxygenase-hemmern
|
US8367112B2
(en)
*
|
2006-02-28 |
2013-02-05 |
Alkermes Pharma Ireland Limited |
Nanoparticulate carverdilol formulations
|
BRPI0712130A2
(pt)
*
|
2006-05-30 |
2012-01-17 |
Elan Pharma Int Ltd |
formulações de posaconazol em nanopartìculas
|
EP2040671B1
(de)
*
|
2006-06-23 |
2018-01-24 |
Janssen Sciences Ireland UC |
Wässrige suspensionen von tmc278
|
TW200820991A
(en)
*
|
2006-07-10 |
2008-05-16 |
Elan Pharma Int Ltd |
Nanoparticulate sorafenib formulations
|
KR20090031618A
(ko)
*
|
2006-07-12 |
2009-03-26 |
엘란 코포레이션, 피엘씨 |
나노입자형 모다피닐 제제
|
EP2101735A2
(de)
*
|
2006-11-28 |
2009-09-23 |
Marinus Pharmaceuticals, Inc. |
Nanoteilchenförmige formulierungen und verfahren zur herstellung und verwendung
|
US20090152176A1
(en)
*
|
2006-12-23 |
2009-06-18 |
Baxter International Inc. |
Magnetic separation of fine particles from compositions
|
TWI494133B
(zh)
*
|
2007-03-14 |
2015-08-01 |
Tibotec Pharm Ltd |
重組用粉末
|
US8426467B2
(en)
*
|
2007-05-22 |
2013-04-23 |
Baxter International Inc. |
Colored esmolol concentrate
|
US8722736B2
(en)
*
|
2007-05-22 |
2014-05-13 |
Baxter International Inc. |
Multi-dose concentrate esmolol with benzyl alcohol
|
US20080293814A1
(en)
*
|
2007-05-22 |
2008-11-27 |
Deepak Tiwari |
Concentrate esmolol
|
US8642062B2
(en)
|
2007-10-31 |
2014-02-04 |
Abbott Cardiovascular Systems Inc. |
Implantable device having a slow dissolving polymer
|
JP2011520779A
(ja)
*
|
2008-03-21 |
2011-07-21 |
エラン・ファルマ・インターナショナル・リミテッド |
イマチニブの部位特異的送達のための組成物および使用の方法
|
GB0818403D0
(en)
*
|
2008-10-08 |
2008-11-12 |
Univ Leuven Kath |
Aqueous electrophoretic deposition
|
WO2010040648A2
(en)
*
|
2008-10-06 |
2010-04-15 |
Katholieke Universiteit Leuven, K.U.Leuven R&D |
Functional layers of biomolecules and living cells, and a novel system to produce such
|
EP3045043B1
(de)
|
2009-02-26 |
2020-04-29 |
Relmada Therapeutics, Inc. |
Oral einnehmbare pharmazeutische zusammensetzungen aus 3-hydroxy-n-methylmorphinan mit verzögerter freisetzung und verwendungsverfahren dafür
|
RU2589823C2
(ru)
*
|
2009-04-09 |
2016-07-10 |
Алкермес Фарма Айэленд Лимитед |
Композиция для доставки лекарственных средств
|
US20100291221A1
(en)
*
|
2009-05-15 |
2010-11-18 |
Robert Owen Cook |
Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
|
FR2945950A1
(fr)
|
2009-05-27 |
2010-12-03 |
Elan Pharma Int Ltd |
Compositions de nanoparticules anticancereuses et procedes pour les preparer
|
JP6072539B2
(ja)
|
2009-05-27 |
2017-02-01 |
アルカーメス ファーマ アイルランド リミテッド |
ナノ粒子活性物質組成物におけるフレーク状凝集の軽減
|
US20120128740A1
(en)
|
2009-06-19 |
2012-05-24 |
Filipcsei Genoveva |
Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
|
BR112012006345A2
(pt)
*
|
2009-09-22 |
2020-08-11 |
Tibotec Pharmaceuticals |
tratamento e prevenção de infecção de hiv
|
MX353096B
(es)
|
2010-08-19 |
2017-12-19 |
Buck Institute For Age Res Star |
Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.
|
WO2012061480A2
(en)
*
|
2010-11-02 |
2012-05-10 |
Board Of Regents Of The University Of Nebraska |
Compositions and methods for the delivery of therapeutics
|
CA2869849A1
(en)
|
2012-04-13 |
2013-10-17 |
Glaxosmithkline Intellectual Property Development Limited |
Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide, vilanterol trifenatate and fluticasone furoate
|
EP2890370B1
(de)
|
2012-08-31 |
2019-10-09 |
The Regents of the University of California |
Mittel zur behandlung von adipositas, diabetes und verwandten erkrankungen
|
WO2015108945A2
(en)
|
2014-01-14 |
2015-07-23 |
Board Of Regents Of The University Of Nebraska |
Compositions and methods for the delivery of therapeutics
|
WO2016057866A1
(en)
|
2014-10-09 |
2016-04-14 |
Board Of Regents Of The University Of Nebraska |
Compositions and methods for the delivery of therapeutics
|
US10166197B2
(en)
|
2015-02-13 |
2019-01-01 |
St. John's University |
Sugar ester nanoparticle stabilizers
|
EP3288957A4
(de)
|
2015-05-01 |
2019-01-23 |
Cocrystal Pharma, Inc. |
Nukleosidanaloga zur behandlung von viren der flaviviidae-familie und krebs
|
WO2017064628A1
(en)
*
|
2015-10-13 |
2017-04-20 |
Hetero Research Foundation |
C-3 novel triterpenone with c-28 urea derivatives as hiv inhibitors
|
TWI678203B
(zh)
*
|
2016-05-31 |
2019-12-01 |
中裕新藥股份有限公司 |
蛋白酶抑制劑之長效醫藥組合物
|
US11839623B2
(en)
|
2018-01-12 |
2023-12-12 |
Board Of Regents Of The University Of Nebraska |
Antiviral prodrugs and formulations thereof
|
US11458136B2
(en)
|
2018-04-09 |
2022-10-04 |
Board Of Regents Of The University Of Nebraska |
Antiviral prodrugs and formulations thereof
|
JP7311448B2
(ja)
*
|
2020-03-13 |
2023-07-19 |
信越化学工業株式会社 |
フィルム成形用組成物及びフィルム
|